Federal contract award
75A50122C00061
PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $220.6M |
| Current contract value | $220.6M |
| Potential contract value / ceiling | $942.5M |
| Start date | Sep 30, 2022 |
| Current end date | Sep 30, 2030 |
| Potential end date | Sep 29, 2032 |
| Latest award activity | Jul 27, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 23 of 23 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 27, 2026 | P00022 | $32.6M | THE PURPOSE OF THIS MODIFICATION IS TO: 1. FUND CLIN 0003A IN THE AMOUNT OF $32,580,161.00 2. UPDATE STATE OF WORK TO SUPPORT THE BUNDIBUGYO OUTBREAK RESPONSE 3. THE CONTRACT IS HEREBY DESIGNATED AS A DPAS RATED ORDER: DO-M3. ISSUE PRIORITY RATI |
| Jul 8, 2026 | P00021 | $3.2M | THE PURPOSE OF THIS MODIFICATION IS TO: 1) TRANSFER OF MATERIAL FROM BARDA CONTRACT NO. 75A50122C00061 (061) TO BARDA CONTRACT NO. HHSO100201600021C (21C). 2) FUND CLIN 0001 IN THE AMOUNT OF $2,841,678.00 AND FUND CLIN 0003A IN THE AMOUNT OF $385, |
| May 28, 2026 | P00020 | $0 | THE PURPOSE OF THIS NO COST MODIFICATION IS TO UPDATE ARTICLE C.1 STATEMENT OF WORK. |
| May 12, 2026 | P00019 | $0 | THE PURPOSE OF THIS NO COST MODIFICATION TO (1) DRUG SUBSTANCE (DS) AND DRUG PRODUCT (DP) MATERIAL TO BE REMOVED FROM CLINICAL SUPPLY TO QUARANTINE STATUS, (2) TRANSFER GOVERNMENT FURNISHED PROPERTY TO MAPP FOR FURTHER IN-HOUSE DEVELOPMENT, (3) UPDAT |
| Mar 12, 2026 | P00018 | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - TRANSFER GFP TO MAPP CONTACT 21C, EXTEND POP FOR CLIN 0001 & 0006 |
| Jul 11, 2025 | P00017 | $49.9M | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - TRANSFER GFP |
| Apr 18, 2025 | P00016 | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - TRANSFER GFP |
| Apr 1, 2025 | P00015 | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - TRANSFER GFP |
| Mar 10, 2025 | P00014 | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - INCORPORATE NEW SOW, UPDATE QUALITY AGREEMENT |
| Jan 13, 2025 | P00013 | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - INCORPORATE NEW SOW |
| Dec 5, 2024 | P00012 | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - INCORPORATE RATE LETTER MOD |
| Aug 7, 2024 | P00011 | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - INCORPORATE RATE LETTER MOD |
| Jun 3, 2024 | P00010 | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - TRANSFER PROPERTY MOD |
| May 28, 2024 | P00009 | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - TRANSFER PROPERTY MOD |
| May 15, 2024 | P00008 | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES |
| May 9, 2024 | P00007 | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES |
| Dec 14, 2023 | P00006 | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES |
| Sep 22, 2023 | P00005 | $8.6M | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES |
| Mar 7, 2023 | P00004 | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES |
| Feb 19, 2023 | P00003 | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES |
| Dec 22, 2022 | P00002 | $16.5M | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES |
| Oct 12, 2022 | P00001 | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES |
| Sep 27, 2022 | 0 | $109.8M | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES |
Estimated positioning window
Sep 29, 2031 – Mar 29, 2032
Recompete signal: . Rule-based research score; positioning dates are estimates.
50/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 50/100. Available recorded signals: 45 points.
- Contract end 2032-09-29 (2159 days from calculation)
- +5 points
- 25 historical awards in this buyer and category group
- +15 points
- 23 recorded award transactions
- +10 points
- Latest award action: 2026-07-27
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.